Actavis has decided to give Icelandic health institutions a gift by offering the company’s first hypodermic cancer drugs on the Icelandic market for free. A year’s supply of five different drugs is being made available to Icelandic health institutions without charge: four from 1st April 2009 and one from 1st January 2010. Read the full story

Actavis Group and Japan’s ASKA Pharmaceutical have formally signed an agreement establishing a joint company: Actavis ASKA K.K. with its head office in Tokyo. The preliminary agreement was signed last November. Read the full story

Clamelle Chlamydia Test Kits will soon be available in UK pharmacies allowing customers to test for Chlamydia without the need to visit a doctor or hospital. Read the full story

Actavis announced a preliminary agreement with ASKA Pharmaceutical concerning the establishment of a joint company: Actavis ASKA Co., Ltd. The plan is to enter the Japanese generic pharmaceutical market in April 2009. Read the full story

New analytical and research and development laboratories were opened in a United States division of the international generic pharmaceutical company Actavis.

The labs help expand the research and development efforts for controlled release drugs and other technically difficult generic pharmaceutical products. Read the full story

The international generic pharmaceuticals company, Actavis has entered into an exclusive distribution agreement with J&M Pharma, a Korean owned and operated pharmaceutical company, headquartered in Seoul, Korea. Read the full story

The operations of generic pharmaceutical company Actavis will not be affected by the financial crisis in Iceland, the company reports.

Actavis, which has its headquarters in Reykjavik, is a leading generic pharmaceuticals manufacturer with operations in 40 countries and 11,000 employees.

Read the full story

Actavis, a generic drugs manufacturer based in Iceland, has received approval from the US Food & Drug Administration to market the generic breast cancer drug, Epirubicin Hydrochloride Injection, in the United States.

The drug will be Actavis’ second oncology drug introduced to the US this year.

Epirubicin Hydrochloride Injection, the generic to Pfizer’s Ellence, is prescribed to patients with evidence of axillary node tumours following resection of primary breast cancer.

Read the full story

Actavis, the generic drug manufacturer, has announced it has reduced the price of 40 pharmaceuticals on the Icelandic market from 1st October.

The move is a result of changes to Icelandic pharmaceutical laws which took effect from the beginning of this month. The reductions are similar to those that the company announced in May this year.

Read the full story

Employees from many of Actavis Group‘s diverse departments worldwide will be present at this year’s annual CPhI conference, which is held in Frankfurt, Germany, from today until 2 October.

Medis – Actavis’ third party sales division — had its own stand at the CPhI exhibition for 8 years, but shared the floor with Actavis Group last year for the first time. Actavis and Medis employees will take part in the CPhI conference, the world’s leading pharmaceutical trade conference, now in its 19th year.

Read the full story